Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
-
- Marco Falcone
- Department of Clinical and Experimental Medicine, University of Pisa, Infectious Diseases Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
-
- Giusy Tiseo
- Department of Clinical and Experimental Medicine, University of Pisa, Infectious Diseases Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
-
- Alessandro Leonildi
- Microbiology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
-
- Leonardo Della Sala
- Department of Clinical and Experimental Medicine, University of Pisa, Infectious Diseases Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
-
- Alessandra Vecchione
- Microbiology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
-
- Simona Barnini
- Microbiology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
-
- Alessio Farcomeni
- Department of Economics and Finance, University of Rome “Tor Vergata,” Rome, Italy
-
- Francesco Menichetti
- Department of Clinical and Experimental Medicine, University of Pisa, Infectious Diseases Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
書誌事項
- 公開日
- 2022-05-17
- 権利情報
-
- https://doi.org/10.1128/ASMCopyrightv2
- https://journals.asm.org/non-commercial-tdm-license
- DOI
-
- 10.1128/aac.02142-21
- 公開者
- American Society for Microbiology
この論文をさがす
説明
<jats:p> Cefiderocol may represent a therapeutic option for carbapenem-resistant <jats:named-content content-type="genus-species">Acinetobacter baumannii</jats:named-content> (CRAB) infections, but clinical data are limited. This is an observational retrospective study conducted in the University Hospital of Pisa including consecutive patients with CRAB infections (January 2020 to August 2021). </jats:p>
収録刊行物
-
- Antimicrobial Agents and Chemotherapy
-
Antimicrobial Agents and Chemotherapy 66 (5), 2022-05-17
American Society for Microbiology